73 related articles for article (PubMed ID: 23282970)
1. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
Hsu CY; Lin SC; Ho HL; Chang-Chien YC; Hsu SP; Yen YS; Chen MH; Guo WY; Ho DM
Am J Surg Pathol; 2013 Feb; 37(2):264-71. PubMed ID: 23282970
[TBL] [Abstract][Full Text] [Related]
2. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.
Melguizo C; Prados J; González B; Ortiz R; Concha A; Alvarez PJ; Madeddu R; Perazzoli G; Oliver JA; López R; Rodríguez-Serrano F; Aránega A
J Transl Med; 2012 Dec; 10():250. PubMed ID: 23245659
[TBL] [Abstract][Full Text] [Related]
3. USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization.
Liu J; Wang K; Zhu Q; Zhang Y; Chen Y; Lou Z; Yuan J
CNS Neurosci Ther; 2024 Apr; 30(4):e14711. PubMed ID: 38644551
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide DNA methylation analysis identifies potent CpG signature for temzolomide response in non-G-CIMP glioblastomas with unmethylated MGMT promoter: MGMT-dependent roles of GPR81.
Liang BB; Wang YH; Huang JJ; Lin S; Mao GC; Zhou ZJ; Yan WJ; Shan CY; Wu HZ; Etcheverry A; He YL; Liu FF; Kang HF; Yin AA; Zhang SQ
CNS Neurosci Ther; 2024 Apr; 30(4):e14465. PubMed ID: 37830163
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma.
Oliver JA; Ortiz R; Melguizo C; Alvarez PJ; Gómez-Millán J; Prados J
BMC Cancer; 2014 Jul; 14():511. PubMed ID: 25015560
[TBL] [Abstract][Full Text] [Related]
6. Radiation and concomitant chemotherapy for patients with glioblastoma multiforme.
Villà S; Balañà C; Comas S
Chin J Cancer; 2014 Jan; 33(1):25-31. PubMed ID: 24325790
[TBL] [Abstract][Full Text] [Related]
7. MGMT inhibition regulates radioresponse in GBM, GSC, and melanoma.
Yun HS; Kramp TR; Palanichamy K; Tofilon PJ; Camphausen K
Sci Rep; 2024 May; 14(1):12363. PubMed ID: 38811596
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management.
Rosas-Alonso R; Colmenarejo-Fernández J; Pernía O; Burdiel M; Rodríguez-Antolín C; Losantos-García I; Rubio T; Moreno-Velasco R; Esteban-Rodríguez I; Martínez-Marín V; Yubero P; Costa-Fraga N; Díaz-Lagares A; López-López R; Díaz-Martin E; García JF; Sánchez CV; Gandía-González ML; Moreno-Bueno G; de Castro J; de Cáceres II
Sci Rep; 2024 May; 14(1):11398. PubMed ID: 38762534
[TBL] [Abstract][Full Text] [Related]
9. Residual Deep Convolutional Neural Network Predicts MGMT Methylation Status.
Korfiatis P; Kline TL; Lachance DH; Parney IF; Buckner JC; Erickson BJ
J Digit Imaging; 2017 Oct; 30(5):622-628. PubMed ID: 28785873
[TBL] [Abstract][Full Text] [Related]
10. The impact of survivorship bias in glioblastoma research.
Pasqualetti F; Barberis A; Zanotti S; Montemurro N; De Salvo GL; Soffietti R; Mazzanti CM; Ius T; Caffo M; Paiar F; Bocci G; Lombardi G; Harris AL; Buffa FM
Crit Rev Oncol Hematol; 2023 Aug; 188():104065. PubMed ID: 37392899
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of glioblastoma with faint MGMT methylation-specific PCR product.
Hsu CY; Ho HL; Lin SC; Chang-Chien YC; Chen MH; Hsu SP; Yen YS; Guo WY; Ho DM
J Neurooncol; 2015 Mar; 122(1):179-88. PubMed ID: 25575938
[TBL] [Abstract][Full Text] [Related]
12. MGMT promoter methylation in non-neoplastic brain.
Hsu CY; Ho HL; Chang-Chien YC; Chang YW; Ho DM
J Neurooncol; 2015 Feb; 121(3):459-67. PubMed ID: 25391970
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.
McAleenan A; Kelly C; Spiga F; Kernohan A; Cheng HY; Dawson S; Schmidt L; Robinson T; Brandner S; Faulkner CL; Wragg C; Jefferies S; Howell A; Vale L; Higgins JPT; Kurian KM
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013316. PubMed ID: 33710615
[TBL] [Abstract][Full Text] [Related]
14. The oncogene BCL6 is up-regulated in glioblastoma in response to DNA damage, and drives survival after therapy.
Fabre MS; Stanton NM; Slatter TL; Lee S; Senanayake D; Gordon RMA; Castro ML; Rowe MR; Taha A; Royds JA; Hung N; Melnick AM; McConnell MJ
PLoS One; 2020; 15(4):e0231470. PubMed ID: 32320427
[TBL] [Abstract][Full Text] [Related]
15. Predictive markers for MGMT promoter methylation in glioblastomas.
Kanazawa T; Minami Y; Jinzaki M; Toda M; Yoshida K; Sasaki H
Neurosurg Rev; 2019 Dec; 42(4):867-876. PubMed ID: 30673883
[TBL] [Abstract][Full Text] [Related]
16. MGMT: Immunohistochemical Detection in High-Grade Astrocytomas.
Lipp ES; Healy P; Austin A; Clark A; Dalton T; Perkinson K; Herndon JE; Friedman HS; Friedman AH; Bigner DD; McLendon RE
J Neuropathol Exp Neurol; 2019 Jan; 78(1):57-64. PubMed ID: 30500933
[TBL] [Abstract][Full Text] [Related]
17. An intronic genetic variation of
Huang L; Xu W; Dai L; Yan D; Zhang S; Shi X
Cancer Manag Res; 2018; 10():3995-4003. PubMed ID: 30310321
[TBL] [Abstract][Full Text] [Related]
18. The MGMT promoter single-nucleotide polymorphism rs1625649 had prognostic impact on patients with MGMT methylated glioblastoma.
Hsu CY; Ho HL; Lin SC; Ho TD; Ho DM
PLoS One; 2017; 12(10):e0186430. PubMed ID: 29036186
[TBL] [Abstract][Full Text] [Related]
19. Relationship between MGMT gene expression and treatment effectiveness and prognosis in glioma.
Li Q; Guo J; Wang W; Wang D
Oncol Lett; 2017 Jul; 14(1):229-233. PubMed ID: 28693158
[TBL] [Abstract][Full Text] [Related]
20. Telomere profiles and tumor-associated macrophages with different immune signatures affect prognosis in glioblastoma.
Hung NA; Eiholzer RA; Kirs S; Zhou J; Ward-Hartstonge K; Wiles AK; Frampton CM; Taha A; Royds JA; Slatter TL
Mod Pathol; 2016 Mar; 29(3):212-26. PubMed ID: 26769142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
